Adhera Therapeutics (ATRX) S-1 28 Aug 15 IPO registration Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Marina Biotech, Inc.
Entity Central Index Key	737,207
Entity Filer Category	Smaller Reporting Company
Document Type	S1
Amendment Flag	false
Document Period End Date	Jun. 30, 2015

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$ 726	$ 1,824	$ 909
Accounts receivable		500	5
Prepaid expenses and other current assets	$ 83	192	128
Total current assets	809	2,516	1,042
Intangible assets	6,700	6,700	6,700
Other Assets	45
Total assets	7,554	9,216	7,742
Current liabilities:
Accounts payable	502	687	1,614
Accrued payroll and employee benefits	271	183	1,505
Accrued interest			147
Other accrued liabilities	1,349	1,072	1,315
Accrued restructuring			12
Notes payable			1,615
Other debt			8
Total current liabilities	2,122	1,942	6,216
Fair value liability for price adjustable warrants	$ 5,582	9,225	5,226
Fair value of stock to be issued to settle liabilities		75	1,019
Deferred tax liabilities	$ 2,345	2,345	2,345
Total liabilities	$ 10,049	$ 13,587	$ 14,806
Commitments and contingencies
Stockholders' deficit:
Common stock, $0.006 par value; 180,000,000 shares authorized, 16,937,661 and 25,523,216 shares issued and outstanding at December 31, 2013, 25,523,216 and 26,451,237 shares issued and outstanding at December 31, 2014 and June 30, 2015, respectively	$ 159	$ 153	$ 102
Additional paid-in capital	333,816	333,264	324,145
Accumulated deficit	(336,470)	(337,788)	(331,311)
Total stockholders' deficit	(2,495)	(4,371)	(7,064)
Total liabilities and stockholders' deficit	$ 7,554	$ 9,216	$ 7,742
Series C Preferred Stock
Stockholders' deficit:
Preferred stock, $.01 par value; 100,000 shares authorized, 0 and 1,200 shares of Series C convertible preferred stock issued and outstanding at December 31, 2013, Series C convertible preferred stock, $.01 par value; 100,000 shares authorized, 1,200 and 1,110 shares issued and outstanding at December 31, 2014 and June 30, 2015, respectively (preference in liquidation of $5,550,000 at June 30, 2015)

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$ 0.006	$ 0.006	$ 0.006
Common stock, shares authorized	180,000,000	180,000,000	180,000,000
Common stock, shares issued	26,451,237	25,523,216	16,937,661
Common stock, shares outstanding	26,451,237	25,523,216	16,937,661
Series C Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000	100,000
Preferred stock, shares issued	1,110	1,200	0
Preferred stock, shares outstanding	1,110	1,200	0
Liquidation preference of series C convertible preferred stock (in dollars)	$ 5,550,000	$ 6,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenue:
License and milestone	$ 400		$ 400		$ 500	$ 2,115
Operating expenses:
Research and development	230	$ 49	484	$ 95	686	715
General and administrative	1,192	622	2,253	1,139	3,334	1,765
Total operating expenses	1,422	671	2,737	1,234	4,020	2,480
Loss from operations	$ (1,022)	$ (671)	(2,337)	(1,234)	(3,520)	(365)
Other income (expense):
Interest and other expense				(1,007)	(1,006)	(249)
Change in fair value liability for price adjustable warrants	$ 1,914	$ 4,545	$ 3,643	(769)	13	151
Change in fair value of stock reserved for issuance to settle liabilities				(2,455)	(2,503)	31
Change in fair value of embedded features in notes payable and amendments to notes payable						829
Gain on foreign exchange transactions		$ 2		2
Gain (loss) on debt extinguishment				4	5	(2,037)
Gain on equipment disposal						30
Gain on settled liabilities	$ 12	45	$ 12	302	534
Total other income (expense), net	1,926	4,592	3,655	(3,923)	(2,957)	(1,245)
Loss before income tax	$ 904	$ 3,921	$ 1,318	$ (5,157)	$ (6,477)	(1,610)
Income tax benefit						(39)
Net loss	$ 904	$ 3,921	$ 1,318	$ (5,157)	$ (6,477)	(1,571)
Deemed dividend related to discount on beneficial conversion feature in Series C convertible preferred shares				(6,000)
Net income (loss) applicable to common stockholders	$ 904	$ 3,921	$ 1,318	$ (11,157)	$ (6,477)	$ (1,571)
Net income (loss) per common share
Basic (in dollars per share)	$ 0.03	$ 0.15	$ 0.05	$ (0.47)
Diluted (in dollars per share)	$ (0.03)	$ 0.11	$ (0.08)	$ (0.47)
Net loss per common share - basic and diluted (in dollars per share)					$ (0.26)	$ (0.09)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic (in shares)	26,036,000	25,633,000	26,036,000	23,563,000
Diluted (in shares)	30,293,000	34,801,000	30,293,000	23,563,000
Shares used in computing net loss per share - basic and diluted (in shares)					24,634,535	16,937,661

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Preferred Stock, par value $0.01	Common Stock, par value $0.006	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2012		$ 102	$ 324,010	$ (329,740)	$ (5,628)
Balance (in shares) at Dec. 31, 2012		16,937,661
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation related to stock options			135		135
Net loss				(1,571)	(1,571)
Balance at Dec. 31, 2013		$ 102	324,145	(331,311)	$ (7,064)
Balance (in shares) at Dec. 31, 2013		16,937,661			16,937,661
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Series C convertible preferred stock, net of issuance costs of $71			5,929		$ 5,929
Issuance of Series C convertible preferred stock, net of issuance costs of $71 (in shares)	1,200
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Stock			(5,929)		(5,929)
Shares issued in connection with lease termination		$ 9	1,851		1,860
Shares issued in connection with lease termination (in shares)		1,500,000
Shares issued in connection with director and management compensation		$ 15	882		897
Shares issued in connection with director and management compensation (in shares)		2,473,854
Shares issued in connection with science advisory board compensation		$ 1	55		56
Shares issued in connection with science advisory board compensation (in shares)		107,988
Shares issued in connection with consulting services			19		19
Shares issued in connection with consulting services (in shares)		39,945
Shares issued in connection with warrant exercises		$ 8	1,930		1,938
Shares issued in connection with warrant exercises (in shares)		1,405,706
Shares issued in connection with licensing and vendor payables		$ 6	1,667		1,673
Shares issued in connection with licensing and vendor payables (in shares)		1,098,673
Shares issued in debt conversion		$ 12	1,467		1,479
Shares issued in debt conversion (in shares)		1,959,389
Beneficial debt conversion feature			971		971
Compensation related to stock options			277		277
Net loss				(6,477)	(6,477)
Balance at Dec. 31, 2014		$ 153	$ 333,264	$ (337,788)	$ (4,371)
Balance (in shares) at Dec. 31, 2014	1,200	25,523,216			25,523,216
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					$ 1,318
Balance at Jun. 30, 2015					$ (2,495)
Balance (in shares) at Jun. 30, 2015					26,451,237

CONSOLIDATED STATEMENT OF STOC6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$ 0.006	$ 0.006
Series C Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Series C convertible preferred stock, issuance costs	$ 71

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net income (loss)	$ 1,318	$ (5,157)	$ (6,477)	$ (1,571)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash (gain) on debt extinguishment		(4)	(5)	2,037
Non-cash interest expense		1,007	1,006	249
Non-cash license expense	$ 120
Non-cash gain on settlement of liabilities	(12)	(302)	(534)
Deferred income tax benefit				(39)
Compensation related to stock options and warrants	$ 296	107	277	135
Gain on disposition of property and equipment				(30)
Gain on foreign exchange transactions		(2)
Changes in fair market value of liabilities:
Stock reserved for issuance to settle liabilities		2,455	2,503	(31)
Embedded debt features				(829)
Price adjustable warrants	$ (3,643)	769	(13)	(151)
Cash changes in assets and liabilities
Accounts receivable	500	5	(495)	2
Prepaid expenses and other assets	64	43	(181)	22
Accounts payable	(173)	(561)	(563)	8
Deferred revenue				(115)
Accrued restructuring			(12)	(380)
Accrued and other liabilities	431	(626)	(285)	978
Net cash used in operating activities	$ (1,099)	$ (2,266)	$ (4,779)	285
Investing activities:
Change in restricted cash				380
Proceeds from the sale of property and equipment				30
Net cash provided by investing activities				410
Financing activities:
Proceeds from sales of Series C preferred shares and warrants, net		$ 5,929	$ 5,929
Cash payments of notes payable		(250)	(250)
Cash proceeds from exercise of warrants			23
Insurance financing		$ (5)	(8)	(2)
Proceeds from exercise of warrants for common stock	$ 1
Net cash provided by financing activities	1	$ 5,674	5,694	(2)
Net increase (decrease) in cash	(1,098)	3,408	915	693
Cash and cash equivalents - beginning of year	1,824	909	909	216
Cash and cash equivalents - end of year	$ 726	4,317	1,824	909
Supplemental disclosure of cash flow information and non-cash financing activities:
Cash paid for interest		83	83	$ 1
Reclassification of fair value liability for price adjustable warrants exercised		1,862	1,917
Issuance of common stock to settle liabilities	$ 195	$ 3,474	3,517
Fair value of warrants issued to purchase common stock to settle liabilities	$ 65
Debt conversion to common stock		$ 1,479	1,479
Deemed dividend to Series C convertible preferred stockholders		$ 6,000	$ 6,000
Par value of common stock issued upon conversion of Series C convertible preferred stock	$ 4

Business, Liquidity and Summary

Business, Liquidity and Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business, Liquidity and Summary of Significant Accounting Policies	Note 1 — Business, Liquidity and Summary of Significant Accounting Policies Business We are a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Our pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (“FAP”), for which we have received Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”), and preclinical programs for the treatment of type 1 myotonic dystrophy (“DM1”) and Duchenne muscular dystrophy (“DMD”). Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies in order to establish a novel and differentiated drug discovery platform. This platform allows us to distinguish ourselves from others in the nucleic acid therapeutics area in that we are the only company capable of creating a wide variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA translational inhibition, exon skipping, microRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees. Liquidity The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2015, we had an accumulated deficit of approximately $336.5 million, $110.4 million of which has been accumulated since we focused on RNA therapeutics in June 2008. To the extent that sufficient funding is available, we will continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements and, to a lesser extent, equipment financing facilities and secured loans. In 2014, we funded operations with a combination of the issuance of preferred stock and license-related revenues. At June 30, 2015, we had negative working capital of $1.27 million and $0.73 million in cash. Our resumed operating activities consume the majority of our cash resources. We believe that our current cash resources will enable us to fund our intended operations through March 2016. Our ability to execute our operating plan beyond March 2016 depends on our ability to obtain additional funding. The volatility in our stock price, as well as market conditions in general, could make it difficult for us to raise capital on favorable terms, or at all. If we fail to obtain additional capital when required, we may have to modify, delay or abandon some or all of our planned activities, or terminate our operations. We are currently pursuing both non-dilutive means of obtaining additional capital, primarily from existing and potential future licenses and partnerships, and dilutive means of obtaining additional capital, primarily through the offering of our equity and debt securities. However, there can be no assurance that we will be successful in such endeavors. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of Preparation and Summary of Significant Accounting Policies Basis of Preparation Use of Estimates Fair Value of Financial Instruments We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and June 30, 2015: Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Quoted prices in Level 2 Significant Balance at active markets for Significant other unobservable (In thousands) June 30, 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 5,582 $ - $ - $ 5,582 Total liabilities at fair value $ 5,582 $ - $ - $ 5,582 The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the six-month period ended June 30, 2015: Weighted average as of each measurement date Fair value liability for price Contractual adjustable warrants Exercise Stock life Risk free (in thousands) Price Price Volatility (in years) rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Change in fair value included in Statement of Operations (3,643 ) Balance at June 30, 2015 $ 5,582 $ 0.42 $ 0.59 102 % 2.09 0.70 % Net Income (Loss) per Common Share Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Stock options outstanding 284,505 1,316,106 284,505 1,316,106 Warrants 7,031,058 1,323,291 21,310,695 1,323,291 Convertible preferred stock - 8,000,000 8,000,000 8,000,000 Total 7,315,563 10,639,397 29,595,200 10,639,397 The following is a reconciliation of basic and diluted net income (loss) per share: Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Net income (loss) – numerator basic $ 3,921 $ 904 $ (11,157 ) $ 1,318 Change in fair value liability for price adjustable warrants - (1,914 ) - (3,643 ) Net loss excluding change in fair value liability for price adjustable warrants $ 3,921 $ (1,010 ) $ (11,157 ) $ (2,325 ) Weighted average common shares outstanding – denominator basic 25,633 26,036 23,563 26,036 Assumed conversion of Series C 102 - - - Effect of price adjustable warrants 9,066 4,257 - 4,257 Weighted average dilutive common shares outstanding 34,801 30,293 23,563 30,293 Net income (loss) per common share – basic $ 0.15 $ 0.03 $ (0.47 ) $ 0.05 Net income (loss) per common share – diluted $ 0.11 $ (0.03 ) $ (0.47 ) $ (0.08 )	Note 1 — Business, Liquidity and Summary of Significant Accounting Policies Business We are a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Our pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (“FAP”), for which we have received Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”), and preclinical programs for the treatment of type 1 myotonic dystrophy (“DM1”) and Duchenne muscular dystrophy (“DMD”). Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies in order to establish a novel and differentiated drug discovery platform. This platform allows us to distinguish ourselves from others in the nucleic acid therapeutics area in that we are the only company capable of creating a wide variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA translational inhibition, exon skipping, microRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees. Liquidity The accompanying consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At December 31, 2014, we had an accumulated deficit of approximately $337.8 million, $112.1 million of which has been accumulated since the corporation focused on RNA therapeutics in June 2008. To the extent that sufficient funding is available, we will in the future continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements with other parties and, to a lesser extent, equipment financing facilities and secured loans. In 2014, we funded operations with a combination of issuances of preferred stock and license-related revenues. At December 31, 2014, we had a working capital surplus of $0.6 million and $1.8 million in cash. Our resumed operating activities consumed the majority of our cash resources during 2014. In February 2014, certain debt holders exchanged secured promissory notes in the aggregate principal and interest amount of $1.5 million for 2.0 million shares of our common stock. In addition, in March 2014, we sold 1,200 shares of our Series C Convertible Preferred Stock and 6.0 million warrants to purchase one share of common stock for $0.75 per share, resulting in gross proceeds of $6.0 million. We believe that our current cash resources, which include an upfront licensing fee received from MiNA in January 2015, will enable us to fund our intended operations through July 2015. Our ability to execute our operating plan beyond July 2015 depends on our ability to obtain additional funding. The volatility in our stock price, as well as market conditions in general, could make it difficult for us to raise capital on favorable terms, or at all. If we fail to obtain additional capital when required, we may have to modify, delay or abandon some or all of our planned activities, or terminate our operations. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements included in this prospectus do not include any adjustments that may result from the outcome of this uncertainty. We are currently pursuing both non-dilutive means of obtaining additional capital, primarily from existing and potential future licenses and partnerships, and dilutive means of obtaining additional capital, primarily through the offering of our equity and debt securities. However, there can be no assurance that we will be successful in such endeavors. Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates Restricted Cash Fair Value of Financial Instruments Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and is valued determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes, using the Black-Scholes option pricing model (“Black-Scholes”), using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2014: Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 5,226 $ - $ - $ 5,226 Fair value liability for shares to be issued 1,019 1,019 - - Total liabilities at fair value $ 6,245 $ 1,019 $ - $ 5,226 Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 The following presents the activity in our accrued restructuring liability determined by Level 3 inputs for each of the years ended December 31, 2013 and 2014 (excludes stock to be issued, not carried in this liability account): Facility Related Liabilities (In thousands) 2013 2014 Balance, January 1 $ 392 $ 12 Cash payments (380 ) (12 ) Balance, December 31 $ 12 $ - The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the years ended December 31, 2013 and 2014: Weighted average as of each measurement date Fair value liability for price adjustable warrants (in thousands) Exercise Price Stock Price Volatility Contractual life (in years) Risk free rate Balance at December 31, 2012 $ 4,169 $ 0.28 $ 0.46 146 % 4.64 0.66 % Fair value of warrants issued in connection to amendments to notes payable 1,208 0.28 0.28 140 % 5.50 1.55 % Change in fair value included in consolidated statement of operations (151 ) - - - - - Balance at December 31, 2013 5,226 0.28 0.4 124 % 4.08 1.30 % Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares 5,929 0.75 1.50 123 % 7.0 0.55 % Exercise of Warrants (1,917 ) 0.36 1.14 133 % 3.07 0.77 % Change in fair value included in consolidated statement of operations (13 ) - - - - - Balance at December 31, 2014 $ 9,225 $ 0.42 0.95 121 % 3.51 0.90 % Impairment of Long Lived Assets · For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property and equipment, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and · For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any. Accrued Restructuring — Concentration of Credit Risk and Significant Customers We have been dependent on our collaborative and license agreements with a limited number of third parties for a substantial portion of our revenue, and our discovery and development activities may be delayed or reduced if we do not maintain successful collaborative arrangements. We had $2.1 million in licensing revenue in 2013 with 53% from Mirna Therapeutics, Inc. (“Mirna”), 38% from Arcturus, and 9% from Protiva Biotherapeutics, Inc. (“Tekmira”), a wholly-owned subsidiary of Tekmira Pharmaceuticals Corporation. We had $0.5 million in licensing revenue in 2014 from MiNA Therapeutics, Ltd. (“MiNA”). We maintain our cash in a single bank account. Any amount over the limits insured by the Federal Deposit Insurance Corporation could be at risk in the event of a bank default. Revenue Recognition Revenue from licensing arrangements is recorded when earned based on the specific terms of the contracts. Upfront non-refundable payments, where we are not providing any continuing services as in the case of a license to our IP, are recognized when the license becomes available to the other party. Milestone payments typically represent nonrefundable payments to be received in conjunction with the uncertain achievement of a specific event identified in the contract, such as initiation or completion of specified development activities or specific regulatory actions such as the filing of an Investigational New Drug Application (“IND”). We believe a milestone payment represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part and it is substantive in nature. We recognize such milestone payments as revenue when it becomes due and collection is reasonably assured. Royalty and earn-out payment revenues are generally recognized upon commercial product sales by the licensee as reported by the licensee. R&D Costs Stock-based Compensation Non-employee stock compensation expense is recognized immediately for immediately vested portions of a grant, with the remaining portions recognized on a straight-line basis over the applicable vesting periods. At the end of each financial reporting period prior to vesting, the value of the unvested stock options, as calculated using Black-Scholes, is re-measured using the fair value of our common stock, and the stock-based compensation recognized during the period is adjusted accordingly. Net Loss per Common Share Year Ended December 31, 2013 2014 Stock options outstanding 284,829 1,084,106 Warrants 17,017,601 21,212,813 Common shares underlying Series C convertible preferred stock - 8,000,000 Total 17,302,430 30,296,919 Notes Payable Note amendments and changes must be analyzed for correct accounting application based on our financial condition and the changes in the debt instrument features and terms. For each note amendment, a series of analyses is performed to determine first whether the amendment was a troubled debt restructuring, as defined by conditions of default, our financial state and ability to repay loan, and whether the lender made a concession. If an amendment is not a troubled debt restructuring, then we perform a further analysis to determine if the amended terms are “substantially different” from the existing debt facility. The debt is considered extinguished if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. The new debt instrument is initially recorded at fair value, and that amount is used to determine the debt extinguishment gain or loss recognized and the effective rate of the new instrument. If it is determined that the original and new debt instruments are not substantially different, then a new effective interest rate is determined based on the carrying amount of the original debt instrument resulting from the modification, and the revised cash flows. If the exchange or modification is to be accounted for in the same manner as a debt extinguishment and the new debt instrument is initially recorded at fair value, then the fees paid including the fair value of warrants issued are included in the debt extinguishment gain or loss. If the exchange or modification is not to be accounted for in the same manner as a debt extinguishment, then the fees paid including the fair value of warrants issued are amortized as an adjustment of interest expense over the remaining term of the replacement or modified debt instrument using the interest method. Income Taxes We assess the likelihood that our deferred tax assets will be recovered from existing deferred tax liabilities or future taxable income. Factors we considered in making such an assessment include, but are not limited to, estimated utilization limitations of operating loss and tax credit carry-forwards, expected reversals of deferred tax liabilities, past performance, including our history of operating results, our recent history of generating tax losses, our history of recovering net operating loss carry-forwards for tax purposes and our expectation of future taxable income. We recognize a valuation allowance to reduce such deferred tax assets to amounts that are more likely than not to be ultimately realized. To the extent that we establish a valuation allowance or change this allowance, we would recognize a tax provision or benefit in the consolidated statements of operations. We use our judgment to determine estimates associated with the calculation of our provision or benefit for income taxes, and in our evaluation of the need for a valuation allowance recorded against our net deferred tax assets.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity (Deficit)	Note 2 — Stockholders’ Deficit Preferred Stock In March 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of Series C Preferred, and price adjustable warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million. Each share of Series C Preferred has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Preferred is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments, has no stated dividend rate, is not redeemable and has voting rights on an as-converted basis. To account for the issuance of the Series C Preferred and warrants, we first assessed the terms of the warrants and determined that, due to certain anti-dilution provisions, they should be recorded as derivative liabilities. We determined the fair value of the warrants on the issuance date and recorded a liability of $6.5 million. Since the fair value of the warrants exceed the total proceeds received of $6.0 million, we recorded a loss of $0.5 million upon issuance, which is included in the change in fair value of price adjustable warrants in the consolidated statements of operations. The discount of $6.0 million on the Series C Preferred resulting from the allocation of the entire proceeds to the warrant was accreted as a dividend on the Series C Preferred through the earliest conversion date, which was immediately. The Series C Preferred dividend of $6.0 million was recorded to additional paid-in capital and as a deemed dividend on the Series C Preferred in determining net loss applicable to common stock holders in the consolidated statements of operations. We incurred $0.07 million of stock issuance costs in conjunction with the Series C Preferred, which were netted against the proceeds. Common Stock In January 2015, we issued 0.12 million shares with a value of $0.075 million to Novosom as the equity component owed under our December 2014 license agreement with Mirna Therapeutics. In May 2015, we issued 0.21 million shares with a value of $0.12 million to Novosom as the equity component owed as a result of an accelerated milestone payment under our December 2014 license agreement with MiNA Therapeutics. In June 2015, an investor converted 90 shares of Series C Preferred into 0.6 million shares of common stock. Warrants From January to June 2015, we issued warrants to purchase up to an aggregate of 0.102 million shares to a vendor providing scientific and development consulting services to our company. The fair value of these warrants at issuance was $0.065 million of which $0.05 million was accrued at December 31, 2014. The following table summarizes warrant activity during the six months ended June 30, 2015: Warrant Weighted Exercise Price Outstanding, December 31, 2014 21,212,813 $ 1.19 Exercised warrants (2,500 ) 0.28 Warrants issued to vendor 104,315 0.68 Outstanding, June 30, 2015 21,314,628 $ 1.19 Expiring in 2015 285,345 Expiring in 2016 6,000,000 Expiring in 2017 7,235,622 Expiring thereafter 7,793,661	Note 6 — Stockholders’ Equity Preferred Stock Stockholder Rights Plan Common Stock In March 2014, we issued 0.1 million shares with a fair value of $0.01 million to a vendor under the terms of a 2012 compromise and release agreement. In September 2012, as part of the lease termination agreement, we agreed to issue 1.5 million shares of our common stock to a landlord. The shares were issued in March 2014 at a value of $1.9 million. As part of the asset purchase agreement that we entered into with Novosom in July 2010, we are obligated to pay Novosom 30% of any payments received by us for sub-licensed SMARTICLES® technology. The consideration is payable in a combination of cash (no more than 50% of total due) and common stock (between 50% and 100% of total due), at our discretion. For such consideration related to MiRNA and ProNAi payments received in 2012 and 2013, we issued 0.96 million common shares with a fair value of $1.5 million in March 2014. In January 2014, we issued 2.8 million shares of common stock with fair value of $1.0 million to employees and board members for amounts due under certain employment and board of director agreements, of which 0.3 million shares were repurchased and retired in December 2014 in connection with the satisfaction of tax withholding obligations. In January 2014, we issued 0.09 million shares of common stock with a fair value of $0.03 million to scientific advisory board members for services to be provided during the three months ended March 31, 2014. In January 2014 and April 2014, we issued an aggregate of 0.04 million shares of common stock with a fair value of $0.02 million to consultants for services provided during the six months ended June 30, 2014. In February 2014, we issued an aggregate of 2.0 million shares of common stock with a fair value of $1.48 million on the conversion of outstanding principal and unpaid accrued interest associated with our convertible debt. In April 2014, we issued 0.02 million shares of common stock with a fair value of $0.03 million to scientific advisory board members for services to be provided during the three months ended June 30, 2014. In September 2014, we issued 0.05 million shares of common stock with fair value of $0.06 million to a vendor to settle an outstanding payable under the terms of a 2012 compromise and release agreement. During 2014, we issued 1.32 million shares of common stock upon net share exercises and 0.08 million shares of common stock on cash exercises of warrants. In December 2014, we pledged to issue common stock valued at $0.075 million to Novosom, related to our license agreement with MiNA, for the portion due under its sublicensing agreement. Pricing of the common stock was to occur on receipt of the payment from MiNA. As of December 2014, the pledge was issued as a dollar denominated liability and was not influenced by changes in stock price. This obligation is included in Fair Value of Stock to be Issued to Settle Liabilities at December 31, 2014. Warrants In December 2013, we issued warrants to purchase up to 0.10 million shares of our common stock to a consultant who is our interim chief financial officer. These warrants vest over two years, have a fixed strike price of $0.48, and expire in December 2023. At December 31, 2014, the unvested warrants have a fair value of $0.03 million. In March 2014, in conjunction with the issuance of Series C Preferred, we issued price adjustable warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share. During 2014, we issued 1.32 million shares of common stock upon net share exercises and 0.08 million shares on cash exercises of warrants. In April 2014, we issued warrants to purchase up to 0.075 million shares of our common stock to a vendor. These warrants have a fixed strike price of $0.89 and expire in April 2024. The fair value of these warrants is immaterial. In December 2014, we issued warrants to purchase up to 0.117 million shares to five consultants providing financial, scientific and development consulting services to our company. The fair value of these warrants is immaterial. The following summarizes warrant activity during the years ended December 31, 2013 and 2014. Warrant Shares Weighted Average Outstanding, January 1, 2013 11,916,801 1.71 Issued 5,100,800 0.28 Outstanding, December 31, 2013 17,017,601 1.29 Issued 6,191,500 0.75 Exercised or cancelled (1,996,288 ) 0.36 Outstanding, December 31, 2014 21,212,813 1.19 Expiring in 2015 285,345 Expiring in 2016 - Expiring in 2017 7,235,622 Expiring thereafter 13,691,846

Stock Incentive Plans

Stock Incentive Plans	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stock Incentive Plans [Abstract]
Stock Incentive Plans	Note 3 — Stock Incentive Plans Stock-based Compensation Three months ended June 30, Six months ended June 30, (In thousands) 2014 2015 2014 2015 Research and development $ 10 $ 5 $ 20 $ 31 General and administrative 10 112 20 265 Total $ 20 $ 117 $ 40 $ 296 Stock Options Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2014 1,084,106 $ 5.52 Options Issued 232,000 $ 0.63 Outstanding, June 30, 2015 1,316,106 $ 4.66 Exercisable, June 30, 2015 293,856 $ 17.34 The following table summarizes additional information on our stock options outstanding at June 30, 2015: Options Outstanding Options Exercisable Weighted-Average Remaining Weighted Range of Exercise Number Contractual Life Weighted Average Number Average Prices Outstanding (Years) Exercise Price Exercisable Exercise Price $0.63 - $0.82 252,000 4.50 $ 0.65 126,000 $ 0.65 $0.83 - $1.07 1,019,000 8.00 1.07 124,000 1.07 $1.08 - $2.20 2,500 6.19 2.20 1,250 2.20 $2.21 - $50.00 10,500 2.95 47.60 10,500 47.60 $50.01 - $100.00 10,500 2.95 87.60 10,500 87.60 $100.01 - $200.00 16,000 2.95 141.35 16,000 141.35 $200.01 - $526.40 5,606 2.92 213.63 5,606 213.63 Totals 1,316,106 7.16 $ 4.66 293,856 $ 17.34 Weighted-Average Exercisable Remaining Contractual Life (Years) 4.16 In January 2015, we issued options to purchase of 0.15 million shares of our common stock to non-employee members of our board of directors at an exercise price of $0.635 per share as the annual grant to such directors for their service on our board of directors during 2015, and we issued options to purchase 0.08 million shares of our common stock to the members of our scientific advisory board at an exercise price of $0.63 per share as the annual grant to such persons for their service on our scientific advisory board during 2015. At June 30, 2015, we had $0.64 million of total unrecognized compensation expense related to unvested stock options. We expect to recognize this cost over a weighted average period of 2.0 years. At June 30, 2015, the intrinsic value of options outstanding or exercisable was zero as there were no options outstanding with an exercise price less than $0.48, the per share closing market price of our common stock at that date. No options were exercised during the six months ended June 30, 2015.	Note 7 — Stock Incentive Plans At December 31, 2014, options to purchase up to 1.1 million shares of our common stock were outstanding, and 8.4 million shares were reserved for future awards under our stock incentive plans. Our current stock incentive plans include the 2008 Stock Incentive Plan and the 2014 Long Term Incentive Plan. Under our stock compensation plans, we are authorized to grant options to purchase shares of common stock to our employees, officers and directors and other persons who provide services to us. The options to be granted are designated as either incentive stock options or non-qualified stock options by our board of directors, which also has discretion as to the person to be granted options, the number of shares subject to the options and the terms of the option agreements. Only employees, including officers and part-time employees, may be granted incentive stock options. Under our 2008 and 2014 stock incentive plans , Stock-based Compensation Year Ended December 31, (In thousands) 2013 2014 Research and development $ 53 $ 48 General and administrative 82 229 Total $ 135 $ 277 Stock Options Year Ended December 31, 2013 2014 Shares Weighted Shares Weighted Outstanding on January 1 284,829 $ 39.46 284,829 $ 39.46 Issued - - 1,039,000 1.07 Forfeited/Expired - - (239,723 ) 18.02 Outstanding on December 31 284,829 $ 39.46 1,084,106 $ 5.52 Exercisable as of December 31 246,559 $ 45.28 179,106 $ 28.06 The following table summarizes additional information on our stock options outstanding at December 31, 2014: Options Outstanding Options Exercisable Range of Exercise Number Weighted-Average Weighted Average Number Weighted $0.82 20,000 4.80 $ 0.82 10,000 $ 0.82 $1.07 1,019,000 8.49 1.07 124,000 1.07 $2.00 - $2.20 2,500 6.70 2.20 2,500 2.20 $11.60 - $50.00 10,500 3.44 47.60 10,500 47.60 $50.00 - $90.80 10,500 3.40 87.60 10,500 87.60 $127.60 - $207.60 21,500 3.40 158.30 21,500 158.30 $420.00 - $588.80 106 2.10 526.40 106 526.40 Totals 1,084,106 8.23 $ 5.52 179,106 $ 28.06 Weighted-Average Exercisable Remaining Contractual Life (Years) 4.44 We use Black-Scholes to determine the fair value of our stock-based awards. The determination of the fair value of stock-based awards on the date of grant using an option-pricing model is affected by our stock price, as well as by assumptions regarding a number of complex and subjective variables. We meet the criteria, having had significant past structural changes, such that our historical exercise data are not reasonably extrapolated to an expected term. Given the terms of the awards and the population of recipients, we believe that expected term is equal to the contractual term. We estimate volatility of our common stock by using our stock price history to forecast stock price volatility. The risk-free interest rates used in the valuation model were based on U.S. Treasury issues with terms similar to the expected term on the options. We do not anticipate paying any dividends in the foreseeable future. No options were granted in 2013 and 1.0 million options were granted in 2014. At December 31, 2014, we had $1.6 million of total unrecognized compensation expense related to unvested stock options. We expect to recognize this cost over a weighted average period of 2.0 years. At December 31, 2014, the intrinsic value of options outstanding or exercisable was zero as there were no options outstanding with an exercise price less than the per share closing market price of our common stock at that date. No options were exercised in either 2013 or 2014. The total grant date fair value of options that vested during 2013 and 2014 was $0.15 million and $0.12 million, respectively. In January 2015, we issued options to purchase up to an aggregate of 152,000 shares of our common stock to the non-employee members of our board of directors at an exercise price of $0.635 per share as the annual grant to such directors for their service on our board of directors during 2015, and we issued options to purchase up to an aggregate of 80,000 shares of our common stock to the members of our scientific advisory board at an exercise price of $0.63 per share as the annual grant to such persons for their service on our scientific advisory board during 2015.

Intellectual Property and Colla

Intellectual Property and Collaborative Agreements	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Intellectual Property and Contractual Agreements [Abstract]
Intellectual Property and Collaborative Agreements	Note 4 — Intellectual Property and Collaborative Agreements Novosom	Note 9 — Intellectual Property and Collaborative Agreements MiNA — Arcturus — Tekmira — Mirna Novosom Valeant Pharmaceuticals University of Helsinki

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 5 — Commitments and Contingencies Contingencies	Note 10 — Commitments and Contingencies Standby Letter of Credit/Leases Contingencies

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 6 — Subsequent Events On August 5, 2015, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 220 shares of Series D Preferred, and price adjustable warrants to purchase up to 3.44 million shares of our common stock at an exercise price of $0.40 per share, for an aggregate purchase price of $1.1 million. Each share of Series D Preferred has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.40 per share. The Series D Preferred is initially convertible into an aggregate of 2,750,000 shares of our common stock, subject to certain limitations and adjustments, has a 5% stated dividend rate, is not redeemable and has voting rights on an as-converted basis.	Note 11 — Subsequent Events All material subsequent events have been included within footnotes 1, 6, 7 and 9 of the Consolidated Financial Statements.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Intangible assets	Note 2 — Intangible assets In July 2010, we acquired Cequent. A substantial portion of the assets acquired were allocated to identifiable intangible assets related to in-process research and development (“IPR&D”) projects identified by our chief executive officer. Our chief executive officer estimated acquisition-date fair values of these intangible assets based on a number of factors. Utilizing the income approach, a discounted cash flow model using forecasted operating results related to the identified intangible assets, fair value was determined to be $19.3 million for FAP and $3.4 million for tk We tested the carrying value of our intangible assets for impairment as of December 31, 2013 and 2014, utilizing the income approach. We estimated the fair value of these intangible assets using a discount rate of 22%. We probability adjusted our estimation of the expected future cash flows associated with each project and then determined the present value of the expected future cash flows using the discount rate. The projected cash flows from the projects were based on key assumptions, including those outlined above. As no impairment was indicated, no loss was recorded in 2013. Using a similar analysis with a 22% discount rate, no impairment was indicated at December 31, 2014 and no loss on impairment was recorded in 2014. Deferred Taxes

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	Note 3 — Accrued Expenses The following summarizes the major components of the accrued expenses balance at December 31, 2013 and 2014. Year Ended December 31, 2013 2014 Corporate legal fees $ 138 $ 564 Audit, tax and filing services 454 189 Interest accrued 138 - Taxes and Delaware fees 450 96 Board fees - 45 Consulting equity instruments - 40 Sublicense fees 125 125 Other miscellaneous 10 13 $ 1,315 $ 1,072

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2014
Restructuring Charges (Abstract)
Restructuring Charges	Note 4 — Restructuring Charges In September 2012, we executed a lease termination agreement effective March, 2013 for our Bothell, Washington facility. Under the agreement, the remaining 2012 rent of $0.5 million and remaining 2013 rent of $0.4 million would be paid, mostly by a draw on the letter of credit. Additionally, we agreed to issue 1.5 million shares of our common stock on certain future financing events valued as a charge to restructuring of $0.45 million. The stock was issued on the closing of our March 2014 financing, resulting in a 2014 charge of $1.1 million based on the change in fair value of the stock reserved to settle the liability. The lease termination in 2012 resulted in the elimination of $1.1 million of deferred rent, offset by restructuring future rent charges of $0.85 million and a stock liability of $0.45 million. There were no additional restructuring charges in 2013 or 2014.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	Note 5 — Notes Payable Original Issuance and Amendments Amendments in 2013 During the year ended December 31, 2013, we recorded interest expense related to the notes of $0.25 million, a loss on debt extinguishments of $2.0 million and a gain on the change in the fair value of embedded debt features of $0.8 million. In the year ended December 31, 2014, we recorded interest expense related to the notes of $1.0 million and an immaterial gain on debt extinguishment. In February 2014, the note holders exchanged the notes in the aggregate principal and interest amount of $1.5 million for approximately 2.0 million shares of our common stock.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	Note 8 — Income Taxes We have identified our federal and Massachusetts state tax returns as “major” tax jurisdictions. The periods our income tax returns are first subject to examination for federal and Massachusetts jurisdictions are 2010 and 2005, respectively. We believe our income tax filing positions and deductions will be sustained on audit, and we do not anticipate any adjustments that would result in a material change to our financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. At December 31, 2014, we had available net operating loss carry-forwards for federal and state income tax reporting purposes of $310.0 million and $0.0 million, respectively, and had available tax credit carry-forwards for federal and state income tax reporting purposes of $10.6 million and $0.1 million, which are available to offset future taxable income. Portions of these carry-forwards will expire through 2032 if not otherwise utilized. We have not performed a formal analysis, but our ability to use such net operating losses and tax credit carry-forwards is subject to annual limitations due to change of control provisions under Sections 382 and 383 of the Internal Revenue Code, and such limitation could be significant. Our net deferred tax assets, liabilities and valuation allowance as of December 31, 2013 and 2014 are as follows: Year Ended December 31, (In thousands) 2013 2014 Deferred tax assets: Net operating loss carryforwards $ 108,110 $ 108,348 Tax credit carryforwards 10,783 10,696 Depreciation and amortization 3,605 3,709 Other 78 185 Total deferred tax assets 122,576 122,938 Valuation allowance (122,576 ) (122,938 ) Net deferred tax assets - - Deferred tax liabilities: Intangible assets (2,345 ) (2,345 ) Net deferred tax liabilities $ (2,345 ) $ (2,345 ) We record a valuation allowance in the full amount of deferred tax assets not otherwise offset by deferred tax liabilities that we expect to reverse since realization of such tax benefits has been determined by our management to be less likely than not. The valuation allowance decreased$0.06 million and increased $0.36 million during 2013 and 2014, respectively. Income Tax Expense.

Business, Liquidity and Summa19

Business, Liquidity and Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation		Principles of Consolidation
Basis of Preparation	Basis of Preparation
Use of Estimates	Use of Estimates	Use of Estimates
Restricted Cash		Restricted Cash
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and June 30, 2015: Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Quoted prices in Level 2 Significant Balance at active markets for Significant other unobservable (In thousands) June 30, 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 5,582 $ - $ - $ 5,582 Total liabilities at fair value $ 5,582 $ - $ - $ 5,582 The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the six-month period ended June 30, 2015: Weighted average as of each measurement date Fair value liability for price Contractual adjustable warrants Exercise Stock life Risk free (in thousands) Price Price Volatility (in years) rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Change in fair value included in Statement of Operations (3,643 ) Balance at June 30, 2015 $ 5,582 $ 0.42 $ 0.59 102 % 2.09 0.70 %	Fair Value of Financial Instruments Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Our cash is subject to fair value measurement and is valued determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes, using the Black-Scholes option pricing model (“Black-Scholes”), using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2014: Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 5,226 $ - $ - $ 5,226 Fair value liability for shares to be issued 1,019 1,019 - - Total liabilities at fair value $ 6,245 $ 1,019 $ - $ 5,226 Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 The following presents the activity in our accrued restructuring liability determined by Level 3 inputs for each of the years ended December 31, 2013 and 2014 (excludes stock to be issued, not carried in this liability account): Facility Related Liabilities (In thousands) 2013 2014 Balance, January 1 $ 392 $ 12 Cash payments (380 ) (12 ) Balance, December 31 $ 12 $ - The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the years ended December 31, 2013 and 2014: Weighted average as of each measurement date Fair value Exercise Stock Volatility Contractual Risk free Balance at December 31, 2012 $ 4,169 $ 0.28 $ 0.46 146 % 4.64 0.66 % Fair value of warrants issued in connection to amendments to notes payable 1,208 0.28 0.28 140 % 5.50 1.55 % Change in fair value included in consolidated statement of operations (151 ) - - - - - Balance at December 31, 2013 5,226 0.28 0.4 124 % 4.08 1.30 % Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares 5,929 0.75 1.50 123 % 7.0 0.55 % Exercise of Warrants (1,917 ) 0.36 1.14 133 % 3.07 0.77 % Change in fair value included in consolidated statement of operations (13 ) - - - - - Balance at December 31, 2014 $ 9,225 $ 0.42 0.95 121 % 3.51 0.90 %
Impairment of Long Lived Assets		Impairment of Long Lived Assets · For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property and equipment, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and · For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.
Accrued Restructuring		Accrued Restructuring —
Concentration of Credit Risk and Significant Customers		Concentration of Credit Risk and Significant Customers We have been dependent on our collaborative and license agreements with a limited number of third parties for a substantial portion of our revenue, and our discovery and development activities may be delayed or reduced if we do not maintain successful collaborative arrangements. We had $2.1 million in licensing revenue in 2013 with 53% from Mirna Therapeutics, Inc. (“Mirna”), 38% from Arcturus, and 9% from Protiva Biotherapeutics, Inc. (“Tekmira”), a wholly-owned subsidiary of Tekmira Pharmaceuticals Corporation. We had $0.5 million in licensing revenue in 2014 from MiNA Therapeutics, Ltd. (“MiNA”). We maintain our cash in a single bank account. Any amount over the limits insured by the Federal Deposit Insurance Corporation could be at risk in the event of a bank default.
Revenue Recognition		Revenue Recognition Revenue from licensing arrangements is recorded when earned based on the specific terms of the contracts. Upfront non-refundable payments, where we are not providing any continuing services as in the case of a license to our IP, are recognized when the license becomes available to the other party. Milestone payments typically represent nonrefundable payments to be received in conjunction with the uncertain achievement of a specific event identified in the contract, such as initiation or completion of specified development activities or specific regulatory actions such as the filing of an Investigational New Drug Application (“IND”). We believe a milestone payment represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part and it is substantive in nature. We recognize such milestone payments as revenue when it becomes due and collection is reasonably assured. Royalty and earn-out payment revenues are generally recognized upon commercial product sales by the licensee as reported by the licensee.
R&D Costs		R&D Costs
Stock-based Compensation		Stock-based Compensation Non-employee stock compensation expense is recognized immediately for immediately vested portions of a grant, with the remaining portions recognized on a straight-line basis over the applicable vesting periods. At the end of each financial reporting period prior to vesting, the value of the unvested stock options, as calculated using Black-Scholes, is re-measured using the fair value of our common stock, and the stock-based compensation recognized during the period is adjusted accordingly.
Net Loss per Common Share	Net Income (Loss) per Common Share Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Stock options outstanding 284,505 1,316,106 284,505 1,316,106 Warrants 7,031,058 1,323,291 21,310,695 1,323,291 Convertible preferred stock - 8,000,000 8,000,000 8,000,000 Total 7,315,563 10,639,397 29,595,200 10,639,397 The following is a reconciliation of basic and diluted net income (loss) per share: Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Net income (loss) – numerator basic $ 3,921 $ 904 $ (11,157 ) $ 1,318 Change in fair value liability for price adjustable warrants - (1,914 ) - (3,643 ) Net loss excluding change in fair value liability for price adjustable warrants $ 3,921 $ (1,010 ) $ (11,157 ) $ (2,325 ) Weighted average common shares outstanding – denominator basic 25,633 26,036 23,563 26,036 Assumed conversion of Series C 102 - - - Effect of price adjustable warrants 9,066 4,257 - 4,257 Weighted average dilutive common shares outstanding 34,801 30,293 23,563 30,293 Net income (loss) per common share – basic $ 0.15 $ 0.03 $ (0.47 ) $ 0.05 Net income (loss) per common share – diluted $ 0.11 $ (0.03 ) $ (0.47 ) $ (0.08 )	Net Loss per Common Share Year Ended December 31, 2013 2014 Stock options outstanding 284,829 1,084,106 Warrants 17,017,601 21,212,813 Common shares underlying Series C convertible preferred stock - 8,000,000 Total 17,302,430 30,296,919
Notes Payable		Notes Payable Note amendments and changes must be analyzed for correct accounting application based on our financial condition and the changes in the debt instrument features and terms. For each note amendment, a series of analyses is performed to determine first whether the amendment was a troubled debt restructuring, as defined by conditions of default, our financial state and ability to repay loan, and whether the lender made a concession. If an amendment is not a troubled debt restructuring, then we perform a further analysis to determine if the amended terms are “substantially different” from the existing debt facility. The debt is considered extinguished if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. The new debt instrument is initially recorded at fair value, and that amount is used to determine the debt extinguishment gain or loss recognized and the effective rate of the new instrument. If it is determined that the original and new debt instruments are not substantially different, then a new effective interest rate is determined based on the carrying amount of the original debt instrument resulting from the modification, and the revised cash flows. If the exchange or modification is to be accounted for in the same manner as a debt extinguishment and the new debt instrument is initially recorded at fair value, then the fees paid including the fair value of warrants issued are included in the debt extinguishment gain or loss. If the exchange or modification is not to be accounted for in the same manner as a debt extinguishment, then the fees paid including the fair value of warrants issued are amortized as an adjustment of interest expense over the remaining term of the replacement or modified debt instrument using the interest method.
Income Taxes		Income Taxes We assess the likelihood that our deferred tax assets will be recovered from existing deferred tax liabilities or future taxable income. Factors we considered in making such an assessment include, but are not limited to, estimated utilization limitations of operating loss and tax credit carry-forwards, expected reversals of deferred tax liabilities, past performance, including our history of operating results, our recent history of generating tax losses, our history of recovering net operating loss carry-forwards for tax purposes and our expectation of future taxable income. We recognize a valuation allowance to reduce such deferred tax assets to amounts that are more likely than not to be ultimately realized. To the extent that we establish a valuation allowance or change this allowance, we would recognize a tax provision or benefit in the consolidated statements of operations. We use our judgment to determine estimates associated with the calculation of our provision or benefit for income taxes, and in our evaluation of the need for a valuation allowance recorded against our net deferred tax assets.

Business, Liquidity and Summa20

Business, Liquidity and Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of liabilities measured at fair value on a recurring basis	Level 1 Level 3 Balance at Quoted prices in Level 2 Significant December 31, active markets for Significant other unobservable (In thousands) 2014 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225 Level 1 Level 3 Quoted prices in Level 2 Significant Balance at active markets for Significant other unobservable (In thousands) June 30, 2015 identical assets observable inputs inputs Liabilities: Fair value liability for price adjustable warrants $ 5,582 $ - $ - $ 5,582 Total liabilities at fair value $ 5,582 $ - $ - $ 5,582	Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 5,226 $ - $ - $ 5,226 Fair value liability for shares to be issued 1,019 1,019 - - Total liabilities at fair value $ 6,245 $ 1,019 $ - $ 5,226 Balance at Level 1 Quoted Level 2 Level 3 Liabilities: Fair value liability for price adjustable warrants $ 9,225 $ - $ - $ 9,225 Fair value liability for shares to be issued 75 75 - - Total liabilities at fair value $ 9,300 $ 75 $ - $ 9,225
Schedule of activity of accrued restructuring liability determined by Level 3 inputs		Facility Related Liabilities (In thousands) 2013 2014 Balance, January 1 $ 392 $ 12 Cash payments (380 ) (12 ) Balance, December 31 $ 12 $ -
Schedule of fair value liability of price adjustable warrants determined by Level 3	Weighted average as of each measurement date Fair value liability for price Contractual adjustable warrants Exercise Stock life Risk free (in thousands) Price Price Volatility (in years) rate Balance at December 31, 2014 $ 9,225 $ 0.42 $ 0.95 121 % 3.51 0.90 % Change in fair value included in Statement of Operations (3,643 ) Balance at June 30, 2015 $ 5,582 $ 0.42 $ 0.59 102 % 2.09 0.70 %	Weighted average as of each measurement date Fair value Exercise Stock Volatility Contractual Risk free Balance at December 31, 2012 $ 4,169 $ 0.28 $ 0.46 146 % 4.64 0.66 % Fair value of warrants issued in connection to amendments to notes payable 1,208 0.28 0.28 140 % 5.50 1.55 % Change in fair value included in consolidated statement of operations (151 ) - - - - - Balance at December 31, 2013 5,226 0.28 0.4 124 % 4.08 1.30 % Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares 5,929 0.75 1.50 123 % 7.0 0.55 % Exercise of Warrants (1,917 ) 0.36 1.14 133 % 3.07 0.77 % Change in fair value included in consolidated statement of operations (13 ) - - - - - Balance at December 31, 2014 $ 9,225 $ 0.42 0.95 121 % 3.51 0.90 %
Schedule of anti-dilutive securities	Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Stock options outstanding 284,505 1,316,106 284,505 1,316,106 Warrants 7,031,058 1,323,291 21,310,695 1,323,291 Convertible preferred stock - 8,000,000 8,000,000 8,000,000 Total 7,315,563 10,639,397 29,595,200 10,639,397	Year Ended December 31, 2013 2014 Stock options outstanding 284,829 1,084,106 Warrants 17,017,601 21,212,813 Common shares underlying Series C convertible preferred stock - 8,000,000 Total 17,302,430 30,296,919
Schedule of reconciliation of basic and diluted net income (loss)	Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Net income (loss) – numerator basic $ 3,921 $ 904 $ (11,157 ) $ 1,318 Change in fair value liability for price adjustable warrants - (1,914 ) - (3,643 ) Net loss excluding change in fair value liability for price adjustable warrants $ 3,921 $ (1,010 ) $ (11,157 ) $ (2,325 ) Weighted average common shares outstanding – denominator basic 25,633 26,036 23,563 26,036 Assumed conversion of Series C 102 - - - Effect of price adjustable warrants 9,066 4,257 - 4,257 Weighted average dilutive common shares outstanding 34,801 30,293 23,563 30,293 Net income (loss) per common share – basic $ 0.15 $ 0.03 $ (0.47 ) $ 0.05 Net income (loss) per common share – diluted $ 0.11 $ (0.03 ) $ (0.47 ) $ (0.08 )

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Schedule of warrant related activity	Warrant Weighted Exercise Price Outstanding, December 31, 2014 21,212,813 $ 1.19 Exercised warrants (2,500 ) 0.28 Warrants issued to vendor 104,315 0.68 Outstanding, June 30, 2015 21,314,628 $ 1.19 Expiring in 2015 285,345 Expiring in 2016 6,000,000 Expiring in 2017 7,235,622 Expiring thereafter 7,793,661	Warrant Shares Weighted Average Outstanding, January 1, 2013 11,916,801 1.71 Issued 5,100,800 0.28 Outstanding, December 31, 2013 17,017,601 1.29 Issued 6,191,500 0.75 Exercised or cancelled (1,996,288 ) 0.36 Outstanding, December 31, 2014 21,212,813 1.19 Expiring in 2015 285,345 Expiring in 2016 - Expiring in 2017 7,235,622 Expiring thereafter 13,691,846

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stock Incentive Plans [Abstract]
Schedule of stock-based compensation expense	Three months ended June 30, Six months ended June 30, (In thousands) 2014 2015 2014 2015 Research and development $ 10 $ 5 $ 20 $ 31 General and administrative 10 112 20 265 Total $ 20 $ 117 $ 40 $ 296	Year Ended December 31, (In thousands) 2013 2014 Research and development $ 53 $ 48 General and administrative 82 229 Total $ 135 $ 277
Schedule of stock option activity	Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2014 1,084,106 $ 5.52 Options Issued 232,000 $ 0.63 Outstanding, June 30, 2015 1,316,106 $ 4.66 Exercisable, June 30, 2015 293,856 $ 17.34	Year Ended December 31, 2013 2014 Shares Weighted Shares Weighted Outstanding on January 1 284,829 $ 39.46 284,829 $ 39.46 Issued - - 1,039,000 1.07 Forfeited/Expired - - (239,723 ) 18.02 Outstanding on December 31 284,829 $ 39.46 1,084,106 $ 5.52 Exercisable as of December 31 246,559 $ 45.28 179,106 $ 28.06
Schedule of summary of additional information on stock options outstanding	Options Outstanding Options Exercisable Weighted-Average Remaining Weighted Range of Exercise Number Contractual Life Weighted Average Number Average Prices Outstanding (Years) Exercise Price Exercisable Exercise Price $0.63 - $0.82 252,000 4.50 $ 0.65 126,000 $ 0.65 $0.83 - $1.07 1,019,000 8.00 1.07 124,000 1.07 $1.08 - $2.20 2,500 6.19 2.20 1,250 2.20 $2.21 - $50.00 10,500 2.95 47.60 10,500 47.60 $50.01 - $100.00 10,500 2.95 87.60 10,500 87.60 $100.01 - $200.00 16,000 2.95 141.35 16,000 141.35 $200.01 - $526.40 5,606 2.92 213.63 5,606 213.63 Totals 1,316,106 7.16 $ 4.66 293,856 $ 17.34 Weighted-Average Exercisable Remaining Contractual Life (Years) 4.16	Options Outstanding Options Exercisable Range of Exercise Number Weighted-Average Weighted Average Number Weighted $0.82 20,000 4.80 $ 0.82 10,000 $ 0.82 $1.07 1,019,000 8.49 1.07 124,000 1.07 $2.00 - $2.20 2,500 6.70 2.20 2,500 2.20 $11.60 - $50.00 10,500 3.44 47.60 10,500 47.60 $50.00 - $90.80 10,500 3.40 87.60 10,500 87.60 $127.60 - $207.60 21,500 3.40 158.30 21,500 158.30 $420.00 - $588.80 106 2.10 526.40 106 526.40 Totals 1,084,106 8.23 $ 5.52 179,106 $ 28.06 Weighted-Average Exercisable Remaining Contractual Life (Years) 4.44

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of summary of major components of accrued expenses balance	Year Ended December 31, 2013 2014 Corporate legal fees $ 138 $ 564 Audit, tax and filing services 454 189 Interest accrued 138 - Taxes and Delaware fees 450 96 Board fees - 45 Consulting equity instruments - 40 Sublicense fees 125 125 Other miscellaneous 10 13 $ 1,315 $ 1,072

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Schedule of deferred tax assets, liabilities and valuation allowance	Year Ended December 31, (In thousands) 2013 2014 Deferred tax assets: Net operating loss carryforwards $ 108,110 $ 108,348 Tax credit carryforwards 10,783 10,696 Depreciation and amortization 3,605 3,709 Other 78 185 Total deferred tax assets 122,576 122,938 Valuation allowance (122,576 ) (122,938 ) Net deferred tax assets - - Deferred tax liabilities: Intangible assets (2,345 ) (2,345 ) Net deferred tax liabilities $ (2,345 ) $ (2,345 )

Business, Liquidity and Summa25

Business, Liquidity and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Liabilities:
Fair value liability for price adjustable warrants	$ 5,582	$ 9,225	$ 5,226
Fair value liability for shares to be issued		75	1,019
Fair value on recurring basis
Liabilities:
Fair value liability for price adjustable warrants	$ 5,582	9,225	5,226
Fair value liability for shares to be issued		75	1,019
Total liabilities at fair value	$ 5,582	$ 9,300	$ 6,245
Fair value on recurring basis | Level 1 Quoted prices in active markets for identical assets
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued		$ 75	$ 1,019
Total liabilities at fair value		$ 75	$ 1,019
Fair value on recurring basis | Level 2 Significant other observable inputs
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued
Total liabilities at fair value
Fair value on recurring basis | Level 3 Significant unobservable inputs
Liabilities:
Fair value liability for price adjustable warrants	$ 5,582	$ 9,225	$ 5,226
Fair value liability for shares to be issued
Total liabilities at fair value	$ 5,582	$ 9,225	$ 5,226

Business, Liquidity and Summa26

Business, Liquidity and Summary of Significant Accounting Policies (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair value liability for price adjustable warrants
Beginning Balance		$ 9,225	$ 5,226	$ 5,226
Change in fair value included in Statement of Operations	$ (1,914)	(3,643)
Ending Balance	5,582	5,582		9,225	$ 5,226
Fair Value Liability For Price Adjustable Warrants | Level 3 Significant unobservable inputs
Fair value liability for price adjustable warrants
Beginning Balance		9,225	$ 5,226	5,226	4,169
Fair value of warrants issued in connection to amendments to notes payable					1,208
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares				5,929
Change in fair value included in Statement of Operations		(3,643)		(13)	(151)
Exercise of Warrants				(1,917)
Ending Balance	$ 5,582	$ 5,582		$ 9,225	$ 5,226	$ 4,169
Exercise Price
Beginning Balance		$ 0.42	$ 0.28	$ 0.28	$ 0.28
Fair value of warrants issued in Notes and Warrants Purchase Agreement, exercise price					0.28
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares, ExercisePrice				0.75
Fair value of exercised warrants, exercise price				0.36
Ending Balance	$ 0.42	0.42		0.42	0.28	$ 0.28
Stock Price
Beginning Balance		0.95	$ 0.4	0.4	0.46
Fair value of warrants issued in connection to amendments to notes payable, stock price					0.28
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares, StockPrice				1.50
Fair value of exercised warrants, stock price				1.14
Ending Balance	$ 0.59	$ 0.59		$ 0.95	$ 0.4	$ 0.46
Volatility
Beginning Balance		121.00%	124.00%	124.00%	146.00%
Fair value of warrants issued in connection to amendments to notes payable, volatility					140.00%
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares, Volatility				123.00%
Fair value of exercised warrants, volatility				133.00%
Ending Balance	102.00%	102.00%		121.00%	124.00%	146.00%
Contractual life (in years)
Contractual life (in years)		2 years 1 month 2 days		3 years 6 months 4 days	4 years 29 days	4 years 7 months 21 days
Fair value of warrants issued in connection to amendments to notes payable, term					5 years 6 months
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares, Contractual life				7 years
Fair value of exercised warrants, exercised term				3 years 26 days
Risk free rate
Beginning Balance		0.90%	1.30%	1.30%	0.66%
Fair value of warrants issued in connection to amendments to notes payable, risk free rate					1.55%
Fair value of price-adjustable warrants issued in connection with Series C Convertible Preferred Shares, Risk free rate				0.55%
Fair value of exercised warrants, risk free rate				0.77%
Ending Balance	0.70%	0.70%		0.90%	1.30%	0.66%

Business, Liquidity and Summa27

Business, Liquidity and Summary of Significant Accounting Policies (Details 2) - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	10,639,397	7,315,563	10,639,397	29,595,200	30,296,919	17,302,430
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,316,106	284,505	1,316,106	284,505	1,084,106	284,829
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,323,291	7,031,058	1,323,291	21,310,695	21,212,813	17,017,601
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	8,000,000		8,000,000	8,000,000	8,000,000

Business, Liquidity and Summa28

Business, Liquidity and Summary of Significant Accounting Policies (Details 3) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss) - numerator basic	$ 904	$ 3,921	$ 1,318	$ (11,157)	$ (6,477)	$ (1,571)
Change in fair value liability for price adjustable warrants	(1,914)		(3,643)
Net loss excluding change in fair value liability for price adjustable warrants	$ (1,010)	$ 3,921	$ (2,325)	$ (11,157)
Weighted average common shares outstanding - denominator basic	26,036	25,633	26,036	23,563
Assumed conversion of Series C		102
Effect of price adjustable warrants	4,257	9,066	4,257
Weighted average dilutive common shares outstanding	30,293	34,801	30,293	23,563
Net income (loss) per common share - basic (in dollars per share)	$ 0.03	$ 0.15	$ 0.05	$ (0.47)
Net income (loss) per common share - diluted (in dollars per share)	$ (0.03)	$ 0.11	$ (0.08)	$ (0.47)

Business, Liquidity and Summa29

Business, Liquidity and Summary of Significant Accounting Policies (Details 4) - Accrued Restructuring Liability - Level 3 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, January 1	$ 12	$ 392
Cash payments	$ (12)	(380)
Balance, December 31		$ 12

Business, Liquidity and Summa30

Business, Liquidity and Summary of Significant Accounting Policies (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2014	Feb. 24, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2012	Jun. 30, 2008
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit			$ (337,788)	$ (331,311)	$ (336,470)			$ (110,400)
Working capital surplus (deficit)			600		1,270
Cash			1,824	$ 909	$ 726	$ 4,317	$ 216
Aggregate principal and interest amount of promissory notes		$ 1,500	$ 1,479
Number of shares issuable through promissory notes		2,000,000
Sale of warrants to purchase one share of common stock	6,000,000
Exercise price of warrants	$ 0.75		$ 1.19	$ 1.29	$ 1.19		$ 1.71
Proceeds from sales of common shares and warrants, net	$ 6,000
Interest rate on notes payable			10.00%
Licensing revenue | MiNA
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Licenses Revenue			$ 500
Licensing revenue | Arcturus
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage				38.00%
Licensing revenue | Tekmira
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage				9.00%
Licensing revenue | Mirna
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Licenses Revenue				$ 2,100
Concentration Risk, Percentage				53.00%
Series C Preferred Stock
Business, Going Concern And Summary Of Significant Accounting Policies [Line Items]
Sale of Series C Convertible Preferred Stock to purchase one share of common stock	1,200
Sale of warrants to purchase one share of common stock	6,000,000
Exercise price of warrants	$ 0.75
Proceeds from sales of common shares and warrants, net	$ 6,000

Stockholders' Equity (Deficit31

Stockholders' Equity (Deficit) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of warrants
Beginning balance, outstanding	21,212,813	17,017,601	11,916,801
Issued		6,191,500	5,100,800
Exercised warrants	(2,500)
Exercised or cancelled		(1,996,288)
Warrants issued to vendor	104,315
Ending balance, outstanding	21,314,628	21,212,813	17,017,601
Weighted average exercise price
Beginning balance, outstanding weighted average exercise price	$ 1.19	$ 1.29	$ 1.71
Issued, weighted average exercise price		0.75	0.28
Exercised or cancelled weighted average exercise price		0.36
Exercised warrants	0.28
Warrants issued to vendor	0.68
Ending balance, outstanding weighted average exercise price	$ 1.19	$ 1.19	$ 1.29
Expiring in 2015	285,345	285,345
Expiring in 2016	6,000,000
Expiring in 2017	7,235,622	7,235,622
Expiring thereafter	7,793,661	13,691,846

Stockholders' Equity (Deficit32

Stockholders' Equity (Deficit) (Preferred Stock) (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
Number of shares called by issuing warrants	6,000,000
Proceeds from sales of common shares and warrants, net	$ 6,000
Exercise price of warrants	$ 0.75	$ 1.19		$ 1.19	$ 1.29	$ 1.71
Proceeds to warrant was accreted as a dividend		$ 1
Derivative Liability		6,500
Amount of loss upon issuance		$ 500
Series A Junior Participating Preferred Stock
Class of Stock [Line Items]
Shares issued during period		90,000		90,000
Series B Preferred Stock
Class of Stock [Line Items]
Shares issued during period		1,000		1,000
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized		100,000		100,000	100,000
Shares issued during period	1,200
Number of shares called by issuing warrants	6,000,000
Conversion price per dollar of stated value	$ 0.75
Proceeds from sales of common shares and warrants, net	$ 6,000
Stated value per share of preferred stock	$ 5,000
Exercise price of warrants	$ 0.75
Shares issued upon conversion	8,000,000
Stock issuance costs		$ 70
Proceeds to warrant was accreted as a dividend		6,000
Deemed dividend recorded to additional paid-in capital		$ 6,000

Stockholders' Equity (Deficit33

Stockholders' Equity (Deficit) (Common Stock) (Detail Textuals 1) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

4 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2015

May. 31, 2015

Jan. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Sep. 30, 2012

Mar. 31, 2014

Apr. 30, 2014

Jun. 30, 2015

Dec. 31, 2014

Stockholders' Equity [Abstract]

Number of voting right

one vote

One vote

Value of shares issued to landlord

$ 1,500

Fair value of shares to be issued

$ 1,900

$ 1,900

Stockholders Equity Note [Line Items]

Value of shares issued for services

$ 19

Value of common stock issued in conversion of debt

$ 1,480

Number of common stock issued in conversion of convertible debt

2,000,000

Number of stock issued upon net share exercises

1,320,000

Number of stock issued on cash exercises of warrants

80,000

Series C Preferred Stock

Stockholders Equity Note [Line Items]

Value of common stock issued in conversion of debt

$ 600

Number of common stock issued in conversion of convertible debt

90

Consultants

Stockholders Equity Note [Line Items]

Shares issued as consideration for sub-licensed lipid-delivery technology

40,000

Value of shares issued for services

$ 20

Non-executive

Stockholders Equity Note [Line Items]

Shares issued as consideration for sub-licensed lipid-delivery technology

90,000

Value of shares issued for services

$ 30

Employees and board members

Stockholders Equity Note [Line Items]

Shares issued as consideration for sub-licensed lipid-delivery technology

2,800,000

Value of shares issued for services

$ 1,000

Shares repurchased and retired

300,000

Scientific advisory board members

Stockholders Equity Note [Line Items]

Shares issued as consideration for sub-licensed lipid-delivery technology

20,000

90,000

Value of shares issued for services

$ 30

$ 30

2012 compromise and release agreement

Stockholders Equity Note [Line Items]

Number of share issued to vendor

100,000

Value of share issued to vendor

$ 10

Shares issued as consideration for sub-licensed lipid-delivery technology

50,000

Value of shares issued for services

$ 60

Novosom

Stockholders Equity Note [Line Items]

Description of consideration for sub-licensed lipid-delivery technology

As part of the asset purchase agreement that we entered into with Novosom in July 2010, we are obligated to pay Novosom 30% of any payments received by us for sub-licensed SMARTICLES® technology. The consideration is payable in a combination of cash (no more than 50% of total due) and common stock (between 50% and 100% of total due), at our discretion.

Amount pledged to issue common stock

$ 75

Novosom | December 2014 license agreement with MiNA therapeutics

Stockholders Equity Note [Line Items]

Amount pledged to issue common stock

$ 120

$ 75

Number of common stock issued for settlement

210,000

120,000

MiRNA and ProNAi

Stockholders Equity Note [Line Items]

Number of shares issued in settlement of outstanding payable

960,000

Fair value of shares issued in settlement of outstanding payable

$ 1,500

Stockholders' Equity (Deficit34

Stockholders' Equity (Deficit) (Warrants) (Detail Textuals 2) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2015$ / sharesshares	Dec. 31, 2014USD ($)Consultant$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Apr. 30, 2014$ / sharesshares	Mar. 31, 2014$ / sharesshares	Dec. 31, 2012$ / shares
Stockholders Equity Note [Line Items]
Number of warrants called by common stock								6,000,000
Exercised warrants			(2,500)
Exercise price of warrants | $ / shares		$ 1.19	$ 1.19		$ 1.19	$ 1.29		$ 0.75	$ 1.71
Fair Value Adjustment of Warrants | $			$ (3,643)	$ 769	$ (13)	$ (151)
Number of stock issued upon net share exercises					1,320,000
Number of stock issued on cash exercises of warrants					80,000
Warrants
Stockholders Equity Note [Line Items]
Number of warrants called by common stock						5,000,000
Exercised warrants	2,500
Exercise price of warrants | $ / shares	$ 0.28					$ 0.28
Fair value of unvested warrants | $		$ 30			$ 30
Warrants | Consultant
Stockholders Equity Note [Line Items]
Number of warrants called by common stock		117,000			117,000	100,000
Number of consultant | Consultant		5
Exercise price of warrants | $ / shares						$ 0.48
Warrants, vesting period						2 years
Warrants | Vendor
Stockholders Equity Note [Line Items]
Number of warrants called by common stock			102,000				75,000
Exercise price of warrants | $ / shares							$ 0.89
Fair Value Adjustment of Warrants | $			$ 65		$ 50

Stock Incentive Plans (Stock-Ba

Stock Incentive Plans (Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 117	$ 20	$ 296	$ 40	$ 277	$ 135
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	5	10	31	20	48	53
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 112	$ 10	$ 265	$ 20	$ 229	$ 82

Stock Incentive Plans (Stock Op

Stock Incentive Plans (Stock Option Activity) (Detail 1) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding, beginning balance	1,084,106	284,829	284,829
Options Issued	232,000	1,039,000
Forfeited/Expired		(239,723)
Outstanding, ending balance	1,316,106	1,084,106	284,829
Exercisable	293,856	179,106	246,559
Weighted Average Exercise Price
Outstanding, beginning balance	$ 5.52	$ 39.46	$ 39.46
Options Issued	0.63	1.07
Forfeited/Expired		18.02
Outstanding, ending balance	4.66	5.52	$ 39.46
Exercisable	$ 17.34	$ 28.06	$ 45.28

Stock Incentive Plans (Stock 37

Stock Incentive Plans (Stock options outstanding) (Details 2) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding	1,316,106	1,084,106	284,829	284,829
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	7 years 1 month 28 days	8 years 2 months 23 days
Options Outstanding, Weighted Average Exercise Price	$ 4.66	$ 5.52	$ 39.46	$ 39.46
Options Exercisable, Number Exercisable	293,856	179,106	246,559
Options Exercisable, Weighted Average Exercise Price	$ 17.34	$ 28.06	$ 45.28
Options Outstanding, Weighted-Average Remaining Contractual Life, Exercisable (Years)	4 years 1 month 28 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Weighted-Average Remaining Contractual Life, Exercisable (Years)		4 years 5 months 8 days
Stock options | $0.63 - $0.82
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$ 0.63
Upper range of price	$ 0.82
Options Outstanding, Number Outstanding	252,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	4 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 0.65
Options Exercisable, Number Exercisable	126,000
Options Exercisable, Weighted Average Exercise Price	$ 0.65
Stock options | $0.83 - $1.07
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	0.83
Upper range of price	$ 1.07
Options Outstanding, Number Outstanding	1,019,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	8 years
Options Outstanding, Weighted Average Exercise Price	$ 1.07
Options Exercisable, Number Exercisable	124,000
Options Exercisable, Weighted Average Exercise Price	$ 1.07
Stock options | $1.08 - $2.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	1.08
Upper range of price	$ 2.20
Options Outstanding, Number Outstanding	2,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	6 years 2 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 2.20
Options Exercisable, Number Exercisable	1,250
Options Exercisable, Weighted Average Exercise Price	$ 2.20
Stock options | $2.21 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	2.21
Upper range of price	$ 50
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 11 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 47.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$ 47.60
Stock options | $50.01 - $100.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	50.01
Upper range of price	$ 100
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 11 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 87.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$ 87.60
Stock options | $100.01 - $200.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	100.01
Upper range of price	$ 200
Options Outstanding, Number Outstanding	16,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 11 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 141.35
Options Exercisable, Number Exercisable	16,000
Options Exercisable, Weighted Average Exercise Price	$ 141.35
Stock options | $200.01 - $526.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	200.01
Upper range of price	$ 526.40
Options Outstanding, Number Outstanding	5,606
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	2 years 11 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 213.63
Options Exercisable, Number Exercisable	5,606
Options Exercisable, Weighted Average Exercise Price	$ 213.63
Stock options | $0.82
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding		20,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		4 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price		$ 0.82
Options Exercisable, Number Exercisable		10,000
Options Exercisable, Weighted Average Exercise Price		$ 0.82
Stock options | $1.07
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding		1,019,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		8 years 5 months 27 days
Options Outstanding, Weighted Average Exercise Price		$ 1.07
Options Exercisable, Number Exercisable		124,000
Options Exercisable, Weighted Average Exercise Price		$ 1.07
Stock options | $2.00 - $2.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price		2
Upper range of price		$ 2.20
Options Outstanding, Number Outstanding		2,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		6 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price		$ 2.20
Options Exercisable, Number Exercisable		2,500
Options Exercisable, Weighted Average Exercise Price		$ 2.20
Stock options | $11.60 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price		11.60
Upper range of price		$ 50
Options Outstanding, Number Outstanding		10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		3 years 5 months 9 days
Options Outstanding, Weighted Average Exercise Price		$ 47.60
Options Exercisable, Number Exercisable		10,500
Options Exercisable, Weighted Average Exercise Price		$ 47.60
Stock options | $50.00 - $90.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price		50
Upper range of price		$ 90.80
Options Outstanding, Number Outstanding		10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		3 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price		$ 87.60
Options Exercisable, Number Exercisable		10,500
Options Exercisable, Weighted Average Exercise Price		$ 87.60
Stock options | $127.60 - $207.60
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price		127.60
Upper range of price		$ 207.60
Options Outstanding, Number Outstanding		21,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		3 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price		$ 158.30
Options Exercisable, Number Exercisable		21,500
Options Exercisable, Weighted Average Exercise Price		$ 158.30
Stock options | $420.00 - $588.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price		420
Upper range of price		$ 588.80
Options Outstanding, Number Outstanding		106
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)		2 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price		$ 526.40
Options Exercisable, Number Exercisable		106
Options Exercisable, Weighted Average Exercise Price		$ 526.40

Stock Incentive Plans (Detail T

Stock Incentive Plans (Detail Textuals) - $ / shares	1 Months Ended	6 Months Ended	12 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase		232,000	1,039,000
Options Issued		$ 0.63	$ 1.07
Board of directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	150,000
Options Issued	$ 0.635
Board of directors | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	80,000
Options Issued	$ 0.63

Stock Incentive Plans (Detail39

Stock Incentive Plans (Detail Textuals 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Incentive Plans [Abstract]
Options to purchase shares of common stock outstanding		1,100,000
Issued	232,000	1,039,000
Common stock available for future grants or awards		8,400,000
Term of plan		10 years
Vesting period		3 years
Unrecognized compensation cost related to unvested stock options	$ 640,000	$ 1,600,000
Unrecognized compensation cost related to unvested stock options, recognition period	2 years	2 years
Intrinsic value of options outstanding	$ 0	$ 0
Intrinsic value of options exercisable	$ 0	0
Options outstanding exercise price	$ 0.48
Total grant date fair value of options vested		$ 150,000	$ 120,000

Stock Incentive Plans (Details

Stock Incentive Plans (Details Textuals 2) - $ / shares	1 Months Ended	6 Months Ended	12 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase		232,000	1,039,000
Options Issued		$ 0.63	$ 1.07
Board of directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	150,000
Options Issued	$ 0.635
Board of directors | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	80,000
Options Issued	$ 0.63

Intellectual Property and Col41

Intellectual Property and Collaborative Agreements (Detail Textuals) $ in Millions	1 Months Ended
	Jan. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)Compounds	Aug. 31, 2013USD ($)	Apr. 30, 2013USD ($)	Dec. 31, 2011USD ($)
MiNA
Intellectual Property And Collaborative Agreements [Line Items]
Maximum upfront, clinical, commercialization milestone payments and royalties received		$ 49
MiNA | Subsequent Event
Intellectual Property And Collaborative Agreements [Line Items]
Upfront payment received under license agreement	$ 0.5
Arcturus
Intellectual Property And Collaborative Agreements [Line Items]
Payment received under license agreement				$ 0.8
Tekmira
Intellectual Property And Collaborative Agreements [Line Items]
Upfront payment received under license agreement					$ 0.3
Additional payment received					$ 0.2
Mirna
Intellectual Property And Collaborative Agreements [Line Items]
Upfront payment received under license agreement			$ 1
Maximum upfront, clinical, commercialization milestone payments and royalties received						$ 63
Agreement termination period						60 days
Number of compounds | Compounds			3
Future additional selection upfront payment			$ 0.5

Intellectual Property and Col42

Intellectual Property and Collaborative Agreements (Detail Textuals 1) € in Thousands, shares in Thousands, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

May. 31, 2015USD ($)shares

Jan. 31, 2015USD ($)shares

Dec. 31, 2014USD ($)

Dec. 31, 2011USD ($)

Jul. 31, 2010USD ($)shares

Mar. 31, 2010USD ($)

Jun. 30, 2008EUR (€)

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)shares

Dec. 31, 2012shares

Dec. 31, 2014EUR (€)

Intellectual Property And Collaborative Agreements [Line Items]

Stock issued during period, value, purchase of assets

$ 1,673

Research and development expense

$ 230

$ 49

$ 484

$ 95

686

$ 715

Value of shares issued during period

5,929

Valeant Pharmaceuticals

Intellectual Property And Collaborative Agreements [Line Items]

Annual payment for per assigned patents

50

Threshold limit of earned out payments

$ 5,000

Valeant Pharmaceuticals | First Conformationally Restricted Nucleotide Product

Intellectual Property And Collaborative Agreements [Line Items]

Development milestone payments

$ 5,000

Valeant Pharmaceuticals | Second Conformationally Restricted Nucleotide Product

Intellectual Property And Collaborative Agreements [Line Items]

Development milestone payments

$ 2,000

Novosom

Intellectual Property And Collaborative Agreements [Line Items]

Stock issued during period, shares, purchase of assets | shares

140

Stock issued during period, value, purchase of assets

$ 3,800

Contractual agreements assets acquired payment percentage

30.00%

Assets acquired additional consideration maximum

$ 3,300

Research and development expense

$ 100

Common stock reserved for future issuance as additional consideration | shares

510

Cash payable

$ 150

Additional common stock reserved for future issuance as consideration | shares

450

License fee payable

$ 75

Amount pledged to issue common stock

$ 75

Novosom | December 2014 license agreement with MiNA therapeutics

Intellectual Property And Collaborative Agreements [Line Items]

Cash payable

$ 80

Amount pledged to issue common stock

$ 120

$ 75

Number of common stock issued for settlement | shares

210

120

Novosom | December 2011 license agreement with MiNA therapeutics

Intellectual Property And Collaborative Agreements [Line Items]

Shares issued during period | shares

210

Value of shares issued during period

$ 120

Novosom | Subsequent Event

Intellectual Property And Collaborative Agreements [Line Items]

Number of common stock issued for settlement | shares

120

University of Helsinki

Intellectual Property And Collaborative Agreements [Line Items]

Development milestone payments | €

€ 275

Royalty advance | €

€ 250

Commitments and Contingencies (

Commitments and Contingencies (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2013USD ($)
Letter of credit
Commitments And Contingencies [Line Items]
Drawn by landlord from letter of credit	$ 380

Subsequent Events (Detail Textu

Subsequent Events (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	Aug. 05, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Subsequent Event [Line Items]
Number of shares called by issuing warrants					6,000,000
Exercise price of warrants		$ 1.19		$ 1.19	$ 0.75	$ 1.29	$ 1.71
Proceeds from exercise of warrants for common stock		$ 1
Subsequent Event | Securities Purchase Agreement | Series D Convertible Preferred Stock
Subsequent Event [Line Items]
Shares issued during period	220
Stated value per share of preferred stock	$ 5,000
Shares issued upon conversion	2,750,000
Stated dividend rate	5.00%
Subsequent Event | Securities Purchase Agreement | Common Stock
Subsequent Event [Line Items]
Number of shares called by issuing warrants	3,440,000
Exercise price of warrants	$ 0.40
Proceeds from exercise of warrants for common stock	$ 1,100
Common stock conversion price per share	$ 0.40

Intangible assets (Detail Textu

Intangible assets (Detail Textuals) - Cequent Pharmaceuticals, Inc. - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Jul. 31, 2010
Business Acquisition [Line Items]
Intangible assets				$ 22.7
Fair value discount rate	22.00%	22.00%
Loss on impairment of intangible assets			$ 16
FAP
Business Acquisition [Line Items]
Intangible assets				19.3
tkRNAi
Business Acquisition [Line Items]
Intangible assets				$ 3.4

Intangible assets (Detail Tex46

Intangible assets (Detail Textuals 1) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2010
Business Acquisition [Line Items]
Acquired deferred tax assets for federal and state net operating loss carry-forwards	$ 108,348	$ 108,110
Deferred tax liability	2,345	$ 2,345
Cequent Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Acquired deferred tax assets for federal and state net operating loss carry-forwards	7,000
Tax credit carry-forwards	1,100
Intangible assets			$ 22,700
Deferred tax liability	$ 8,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Corporate legal fees		$ 564	$ 138
Audit, tax and filing services		189	454
Interest accrued			138
Taxes and Delaware fees		96	450
Board fees		45
Consulting equity instruments		40
Sublicense fees		125	125
Other miscellaneous		13	10
Other accrued liabilities, Total	$ 1,349	$ 1,072	$ 1,315

Restructuring Charges (Detail T

Restructuring Charges (Detail Textuals) - Sep. 30, 2012 - Facility - Washington facility - USD ($) $ in Thousands, shares in Millions	Total
Restructuring Cost and Reserve [Line Items]
Restructuring remaining 2012 rent	$ 500
Restructuring remaining 2013 rent	$ 400
Number of shares to be issuable on certain future financing events	1.5
Value of shares to be issuable on certain future financing events	$ 450
Gain on lease termination	1,100
Future rent charges	850
Stock liability	$ 450

Notes Payable (Detail Textuals)

Notes Payable (Detail Textuals) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended	6 Months Ended		12 Months Ended
	Feb. 24, 2014USD ($)shares	Feb. 29, 2012USD ($)Investor$ / sharesshares	Jun. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)$ / shares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / shares	Mar. 31, 2014$ / sharesshares	Aug. 31, 2013$ / sharesshares	Feb. 28, 2013$ / sharesshares	Dec. 31, 2012$ / shares
Debt Instrument [Line Items]
Interest rate on notes payable						10.00%
Number of shares called by issuing warrants								6
Exercise price of warrants | $ / shares			$ 1.19	$ 1.19		$ 1.19	$ 1.29	$ 0.75			$ 1.71
Gain (loss) on debt extinguishment | $					$ 4	$ 5	$ (2,037)
Gain on the change in the fair value of embedded derivatives | $							829
Notes payable, interest expenses | $						1,000	$ 250
Aggregate principal and interest amount of promissory notes | $	$ 1,500					$ 1,479
Number of shares issuable through promissory notes	2
Notes Payable | Price adjustable warrants
Debt Instrument [Line Items]
Notes payable | $		$ 1,500
Interest rate on notes payable		15.00%
Number of investors | Investor		2
Mandatory prepayment of additional price adjustable warrants						0.2
Number of shares called by issuing warrants		3.7				3.2
Exercise price of warrants | $ / shares		$ 0.508				$ 0.28
Term of warrants		5 years
Notes Payable | Price adjustable warrants | Amendment One
Debt Instrument [Line Items]
Number of shares called by issuing warrants										1
Exercise price of warrants | $ / shares										$ 0.28
Notes Payable | Price adjustable warrants | Amendment Two
Debt Instrument [Line Items]
Number of shares called by issuing warrants									4
Exercise price of warrants | $ / shares									$ 0.28

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$ 108,348	$ 108,110
Tax credit carryforwards	10,696	10,783
Depreciation and amortization	3,709	3,605
Other	185	78
Total deferred tax assets	122,938	122,576
Valuation allowance	$ (122,938)	$ (122,576)
Net deferred tax assets
Deferred tax liabilities:
Intangible assets	$ (2,345)	$ (2,345)
Net deferred tax liabilities	$ (2,345)	$ (2,345)

Income Taxes (Detail Textuals)

Income Taxes (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Increase (Decrease) in valuation allowances	$ (360)	$ (60)
Deferred income tax benefit		$ 40
Federal
Income Taxes [Line Items]
Net operating loss carry-forwards	310,000
Available tax credit carry forwards	10,600
State
Income Taxes [Line Items]
Net operating loss carry-forwards	0
Available tax credit carry forwards	$ 100